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PREFACE 
 
 
 
This dissertation is presented in manuscript format. The findings of the study are 
presented in chapter 3, as a manuscript as required by the regulations of the University of 
KwaZulu-Natal. This manuscript was submitted for publication in the Value in Health: 
Regional Issues. The reference list is cited according to the instructions for authors as 
required by the Value in Health: Regional Issues. A complete reference list is included at 
the end of every chapter and according to the reference style of the University of 
KwaZulu-Natal.  
 
The dissertation consists of four chapters as follows: 
x Chapter 1: provides an introduction to the study as well as the aims, objectives 
and a brief overview of the methodology.  
x Chapter 2: provides the literature background to the study.  
x Chapter 3: consists of the results, discussion and conclusion written in a 
manuscript format.  
x Chapter 4: provides the general conclusions, recommendations, limitations and 
strengths of the study.  
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ABSTRACT 
Objective 
The aim of the study is to identify adverse drug reactions attributable to tenofovir- and 
zidovudine-based fixed-dose combinations of highly active anti-retroviral therapy and, 
subsequently, to determine the annual costs incurred managing these adverse drug 
reactions and the budget implications of these costs at an outpatient anti-retroviral clinic 
in Mamelodi, Pretoria.  
Methods  
This retrospective cohort study reviewed de-identified clinical data for adverse drug 
reactions. The study was carried out at Stanza Bopape ARV Clinic in Mamelodi, Pretoria. 
De-identified medical charts of HIV-positive patients were analysed for clinical 
information and laboratory data of adult patients who started on HAART between July 
2017 and June 2018. Data collection commenced in October 2018. 
Based on the costs and the incidence rates of adverse drug reactions observed in the 
analysis, a decision tree model was established to estimate the cost impact of adverse drug 
reaction management on the clinic s budget.  
Results  
A total of 469 patient files were analysed (62% female vs 38% male). The mean age at 
the start of anti-retroviral therapy for the cohort was 36.6yrs (95% CI 35.74-37.45) and  
the mean baseline CD4 count was 380 (95% CI 343-418). Incidence of adverse drug 
reactions to tenofovir- or zidovudine-based fixed-dose combinations of anti-retroviral 
therapy was found to be 24.95%. The ADRs reported with the use of TDF and AZT based 
HAART regimens were rash  (n=45, 27%), decreased glomerular filtration rate (n=34, 
 
iv 
 
21%), trouble sleeping (n=39, 21%), severe diarrhoea (n=19, 12%), nausea and vomitting 
(n=18, 11%), decreased heamoglobin or anaemia (n=4, 2%), headaches (n=4, 2%), 
dizziness (n=2, 5.3%).  
The study revealed that ZAR427.30 was the cost attributed to adverse drug reactions due 
to tenofovir-based regimens whilst ZAR467.94 was the cost attributed to adverse drug 
reactions due to zidovudine-based regimens, per patient, annually. Costs attributed to 
gastro-intestinal related adverse drug reactions were the highest in comparison to other 
adverse drug reactions. Estimated total cost of adverse drug reactions attributed to 
zidovudine-based therapy was ZAR8003.98 (US$556.40) and estimated total cost of 
adverse drug reactions attributed to tenofovir-based anti-retroviral therapy per annum was 
ZAR33 788, 23 (US$2348.80) for 1221patients initiated on antiretroviral therapy between 
July 2017 and June 2018.  
Conclusion  
Despite our estimated costs to the clinic, due to adverse drug reactions, being lower than 
similar studies, there remains a notable budget impact on a resource-limited setting. These 
estimates will allow for cost due to adverse drug reactions caused by tenofovir- and 
zidovudine-based anti-retroviral therapy to be accounted for in budgets at the anti-
retroviral clinic.  
 
Keywords: Adverse drug reactions, cost analysis, highly active anti-retroviral therapy, 
tenofovir, zidovudine. 
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CHAPTER ONE 
INTRODUCTION 
Pharmaceuticals have the innate risk of causing harm (adverse drug reactions) as well as doing 
good (efficacy).1 At every phase of drug development, until  it s end use, the concept of benefit 
outweighing risk is used  to assess whether the pharmaceutical will be prescribed or not.  Benefit-
risk assessment is not limited to the pharmaceuticals  efficacy but also cost implications.1 Costs 
associated with the risk of causing harm (adverse drug reactions) should be included in financial 
benefit-risk assessment.  
1.1 Background and Rationale for this Study 
The costs of pharmaceuticals have been on the rise in the last couple of decades, much to the 
disgruntlement of payers such as governments, as well as advocacy groups who speak on behalf 
of the general population.2 Over the years, there have been calls for transparency in the pricing of 
pharmaceuticals. This has led to organisations and nations setting up regulatory bodies to control 
and set up standards for the pricing of pharmaceuticals. As a result, more research has been carried 
out and published on the costs of pharmaceuticals.2   
Albeit, the increased research on costs of pharmaceuticals, there is still a research gap on the impact 
of adverse drug reactions on these costs. Adverse drug reactions (ADRs) lead to increased 
healthcare costs. Analysis of the costs of pharmaceuticals would be insufficient if the costs of 
adverse drug reactions associated with them are not factored as well.3 Studies on the costs 
attributable to ADRs and the budget impact of these costs are limited especially in South Africa.  
HIV/AIDS has a great level of disease burden on South Africa. According to the UNAIDS data, 
in 2018, South Africa had the largest anti-retroviral therapy programme in the world with just over 
4.8million people on treatment then.4 It is therefore in the interest of the payers that cost of Highly 
Active Anti-Retroviral Therapy (HAART) as well as those of ADRs associated with them are 
known. This is beneficial for budgeting purposes. In order to analyse the budget impact, incidence 
of the ADRs need to be considered. Based on reviewed studies carried out in developing countries 
the incidence of adverse drug reactions to Highly Active Anti-Retroviral Therapy (HAART) 
ranges from 4.6% to 89.8%.4-19 A South African study reported an incidence of adverse drug 
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reactions (ADRs) to HAART as 37%.19 This is a fairly high figure and demonstrates the need to 
analyse the cost involved in medically managing these adverse drug reactions. 
1.2 Research Questions 
This study focused on the following research questions: 
1.2.1 What are the adverse drug reactions (ADRs) attributable to tenofovir- and zidovudine-
based fixed-dose combinations of Highly Active Anti-Retroviral Therapy (HAART) and 
their incidence? 
1.2.2 What are the direct costs of preventing and managing adverse drug reactions for 
tenofovir- and zidovudine-based HAART regimens? 
1.2.3 Impact on ARV clinic budgets in Gauteng. What is the contribution of HAART ADRs 
on the clinic s budget? 
 
1.3 Aims and Objectives of the Study 
The aim of the study is to identify adverse drug reactions attributable to tenofovir and zidovudine-
based fixed-dose combinations of highly active anti-retroviral therapy and subsequently, 
determine the annual costs incurred managing these adverse drug reactions and the budget impact 
of these costs at an outpatient anti-retroviral clinic. 
1.4 Significance of the Study 
This study gives an indication of the direct costs incurred in managing adverse drug reactions 
attributable to fixed-dose combination HAART in an outpatient facility. The National Department 
of Health (NDoH) embarked on a programme to ensure that all HIV positive patients are identified 
through testing as well as initiated on ARVs.  ARV clinics were set up mostly as outpatient 
facilities within easy access to communities. One of the results of this rollout is that an 
unprecedented number of patients where initiated on HAART and the number is still rising. 
HAART increases the life expectancy of HIV positive patients which also means increased 
duration on treatment as well as increased risk of ADRs. This scenario advocates for increasing 
knowledge of the cost implications of ADRs to HAART. 
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Adverse drug reactions are a major cause of patient-related morbidity and mortality as well as 
increased healthcare costs and knowledge of such costs will play a huge role in effective budgeting 
in ARV clinics or facilities. 
 
1.5 Research Methodology 
 
1.5.1 Study Design and Setting. 
A retrospective cohort study was carried out. Stanza Bopape ARV Clinic capture s all medical 
data from the patients  files onto a computer system, i.e. the Tier System. Previously captured 
medical records of enrolled de-identified patients were analysed. Costs incurred (laboratory 
charges and pharmaceutical charges) were extracted from Stanza Bopape Primary Health Clinic s 
accounting system as well as its suppliers such as National Health Laboratory Services (NHLS) 
billing system. 
1.5.2   Data Analysis 
Patients were separated into 2 groups i.e. case and control. Case groups were those patients that 
recorded an ADR, while the controls were those that did not. They were compared for age at 
HAART initiation, baseline CD4, total HAART costs, total laboratory costs and total direct costs 
using the independent sample t-test. 
To estimate the impact of costs attributable to ADRs, a Decision Tree Model was established. 
Based on the results collected, from the above analysis, a novel budget impact model was built in 
Microsoft® Excel®. 
 
1.5.3 Ethical Approval 
Full ethical approval was obtained from the University of Kwazulu-Natal s Biomedical Research 
Ethics Review Committee (BREC) - reference number BE404/17 (Annexure 1) 
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1.5.4 Gate-keeper Approval from Gauteng Department of Health, Tshwane Research 
Committee.  
This study s gatekeeper approval was obtained from the Gauteng Department of Health, Tshwane 
Research Committe  (PROJECT # 61/2018, NHRD REF GP_201805_034). (Annexure 2) 
 
Chapter 1 Summary 
This chapter summarizes the study s rationale and significance, research questions, aims, 
objectives and a brief outline of the research methodology. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Introduction 
Pharmaceuticals are at the centre of ensuring the welfare of patients. They curtail the distress and 
costs that come along with the disease. Their rational use ensures that society can prevent and 
control various diseases.1  Antiretroviral drugs are no exception to this phenomenon. Highly Active 
Anti-Retroviral Therapy (HAART) has significantly improved the health and socioeconomic 
outcomes of the infected population, making HIV a manageable disease. It has reduced morbidity 
and mortality in HIV positive patients significantly. Without therapy, probably more than 90% of 
all HIV+ patients die from AIDS.2  
As well as being an integral part of health care, pharmaceuticals are both a product and an asset 
for trading. They come at a cost for the payer and society as a whole.3  Global healthcare costs have 
been reported to be rising at an alarming rate with costs of pharmaceuticals being at the driving 
centre of the exponential increase.4 This has prompted the need for more data on costs associated 
with pharmaceuticals. 
Costs associated with pharmaceuticals are not the only detrimental factor; pharmaceuticals often 
come with adverse reactions. According to the World Health Organization (WHO), an adverse 
drug reaction (ADR) is defined as ''a response to a drug which is noxious and unintended, and 
which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, 
or the modifications of physiological function.''5 All medicines carry the risk of causing ADRs. 
ADRs are one of the key causes of morbidity and mortality in healthcare.6 The effects of ADRs 
and their management is costly owing to the increased incidence of healthcare utilisation they 
bring. ADRs may also trigger prescription cascades or even hospitalisation. Often unrecognized 
ADRs require the prescription of new medications.7 ADRs are associated with two main inversely 
correlated costs, i.e. the cost of treating diseases due to ADRs and the cost of evading them. When 
one arm increases, the other automatically decreases. The impact and the management of ADRs, 
in the USA, has been reported to cost up to 30.1 billion dollars annually. 8 All these costs need to 
be incorporated when carrying out a pharmacoeconomic evaluation on a pharmaceutical. 
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Different anti-retroviral therapy (ARV) drug classes have different side effects that include lactic 
acidosis, neuropsychiatric symptoms, rash, liver toxicity, and lipid abnormalities, gastrointestinal 
intolerance, glucose abnormalities amongst others. They are at times associated with serious side 
effects, such as osteonecrosis, renal failure, Stevens-Johnson syndrome (SJS) and bone 
demineralization.8-11 The reported economic burden of these ADRs is significant. In the United 
States, the direct cost incurred in treating ADRs to HAART per episode can escalate up to several 
thousand dollars.12-14 In comparison, these costs might be lower in South Africa and other 
developing countries. However, when compared the per capita spending on health, these cost 
associated with ADRs is significantly high.15 
  In an effort to increase knowledge on the economic burden of these ADRs, locally, more studies 
with need to be commissioned.  
2.2 Pharmacovigilance 
2.2.1 History of Pharmacovigilance  
History informs us that, many congenitally deformed babies were born to mothers who had used 
thalidomide during pregnancy. Thalidomide had been marketed for the treatment of nausea during 
pregnancy in the 1950s and 1960s.5 These births led to coming together of the international 
community, through the World Health Organisation, in an effort to deal with drug safety. 
International Drug Monitoring commenced in 1968. The project was set up to ensure the timeous 
reporting of ADRs as well as efficiently alert individual countries to the patterns of ADRs that 
were emerging across the world. These patterns might not be evident from their local data alone.5 
Pharmacovigilance systems were developed in most developed countries following the 
thalidomide catastrophe.5 These systems use spontaneous reporting amongst other methods to 
collect data on ADRs. They analyse, assimilate the available data, and submit it to the WHO 
Collaborating Centre for International Drug Monitoring, known as the Uppsala Monitoring 
Centre.16 
2.2.2 Global Pharmacovigilance 
Pharmacovigilance starts long before a product is introduced onto the market and continues for as 
long as the product remains available in the market. It involves two main phases. These are the 
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pre-marketing/trial phase and post-marketing/approved drug phase.17 The pre-marketing/trial 
phase involves serious adverse events analysis reports during Phase I-III of the drug development 
cycle whilst the post-marketing/approved drug phase involves passive and active surveillance 
during Phase IV of the drug development cycle.17 
The primary focus of pharmacovigilance, in the beginning, was regulatory. This included detecting 
(diagnosing, reporting) ADRs of registered drugs.17 It was set to detect ADRs not observed during 
the pre-marketing studies (Phase I-III). Clinical trials have limitations when it comes to 
discovering and assessing ADRs. These limitations include selection bias, sample size, and limited 
follow-up duration. 17 Due to these limitations, data on ADRs from clinical trials may not 
necessarily reflect the real incidences and variety of ADRs due to the pharmaceutical in question. 
Thus, real data on the safety of the pharmaceuticals may only be deduced when it is used by 
millions of patients in clinical practice.7 
In a real-world setting, after a drug is marketed, case reports and epidemiological studies are used 
to obtain data on ADRs. These have a better chance at unveiling scarce ADRs as well as revealing 
the real incidence rate of common, predicted ADRs. However, these studies have fewer controls, 
in comparison to the clinical trials, resulting in increased difficulty to ascertain the causal 
relationship between the pharmaceutical and the adverse drug reaction.7 Despite these challenges, 
in the post-approval scenario, product safety data must be collected, organized, analysed and 
reported properly. There is value in quantifying incident levels and frequency for identified ADRs 
as this can vary from its pre-marketing occurrence, as alluded to earlier. 18 In addition, there is also 
an emphasis on broadening pharmacovigilance activities to include poor efficacy, prescribing 
errors, incorrect usage, manufacturing or stability standards not met.19 
These above-mentioned activities are major components of post-marketing research or 
surveillance. Post-marketing drug surveillance (PMS) refers to the '' monitoring of drugs once they 
reach the market after clinical trials''. 18 These studies collect and analyse ADRs observed from a 
real-world setting.20 They are of great value in ensuring that relevant and good quality data is 
collected on predicted and unpredicted ADRs, allowing for additional classification of the ADRs. 
This is possible as more information on the ADR is gathered from case to case in a clinical 
setting.21 
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As the biological sciences progressed, in the pre- phases of drug production, pharmacovigilance 
gradually moved towards earlier, cautious consideration of the dangers and possible benefits of 
drugs.21 Technological advancements observed in recent years have allowed for research and 
development of complex medicines. Complex medicines are more accessible to patients than they 
were in previous decades. 21 Being fairly new on the market, there is limited data on the ADRs of 
these complex medicines. At the present stage, pre-marketing research data is mostly used to the 
obtain data on their respective ADRs. Risk evaluation of these complex medicines is warranted. 21 
With complex medicines, pharmacovigilance focus shifts to the pre-marketing stages. These have 
also allowed for more comprehensive risk evaluation and possible benefits in the manufacturing 
phase much earlier. Growing consumer concern for the safety of more advanced medications, 
coupled with emerging research, has led pharmaceutical innovators, regulators, and healthcare 
practitioners to cooperate on the creation of recommendations for improved pharmacovigilance 
and earlier medication risk management.21 
2.2.3 Status of Pharmacovigilance Activities in South Africa 
Developing countries only started developing national pharmacovigilance systems decades later, 
after their developed-world counterparts. South Africa has progressed since becoming a member 
of the International Drug Monitoring Network of the World Health Organization (WHO) in 1992. 
17 Locally, prior to becoming a member of the International Drug Monitoring Network, the 
foundations for the development of a national pharmacovigilance system had been laid in South 
Africa. These included the declaration on the Medicines and Related Substances Control Act 101 
of 1965 and the formation of various committees such as the National Adverse Drug Event 
Monitoring Centre (NADEMC) and a Pharmacovigilance (PV) expert committee, which laid the 
framework and guidelines for passive surveillance of ADRs.17  
HIV/AIDS and TB epidemics catapulted pharmacovigilance activities in South Africa. There was 
a need for knowledge of the risks associated with pharmaceuticals utilised in the implemented 
national programmes, which responded to these epidemics.17 Both the TB epidemic and the HIV 
crisis have acted as primary factors of service delivery innovation, control, and assessment. 22 
Throughout South Africa, these successful monitoring programs were primarily limited to 
studying the effects of HIV and TB drugs. As they progress, they have developed into positive 
pharmacovigilance interventions throughout public health.22 The pharmacovigilance activities 
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involved formation of national registers for collection of clinical data including adverse drug 
reaction observed.22 
Globally there is a transition from solely relying on passive/spontaneous reporting in 
pharmacovigilance to active surveillance. Active surveillance involves patient registries, cohort 
studies amongst other activities. South Africa has also started to introduce patient registries and 
record-linkages in its pharmacovigilance system. 21  
Mehta et al. (2017) highlighted the value of a strong national pharmacovigilance program in 
response to the rising pressures of drug-induced disease. It helps to educate real-world evidence-
based care programs, to enhance the outcomes of chronic diseases such as HIV, Tuberculosis, 
hypertension and diabetes through effective clinical intervention, and to ensure the safety of large-
scale pharmacotherapy such as vaccines.16 
Despite all the years of experience mentioned above, South Africa's pharmacovigilance systems 
need to be improved and streamlined. Pharmaceutical manufacturers, the South African Health 
Products Regulatory Authority (SAHPRA), public healthcare programs as well as healthcare 
professionals carry out pharmacovigilance activities in South Africa.23 Despite having a common 
goal, which is collection and analysis of data on ADRs, these groups have varied objectives. 
Pharmaceutical manufacturers and South African Health Products Regulatory Authority 
(SAHPRA), public healthcare programs, healthcare professionals focus on the pharmaceuticals, 
systems, and patients respectively.23 There is a need for these stakeholders to liaise, pool resources 
and complement each other to improve South Africa's pharmacovigilance status. 
2.2.4 Risk Factors for Adverse Drug Reactions 
ADRs, in general, are classified into two basic types. Type A (on-target) reactions are ''predictable 
from the known pharmacology of the drug and show a clear dose-response relationship''.24 Type 
B (off-target) reactions are ''those that are difficult to predict from the known pharmacology of the 
drug''.24 Type B ADRs are usually detected after the drug is marketed and show no clear dose-
response relationship. Their etymology is usually more complex than the Type A ADRs.24 ADRs, 
in general, have a complex etymology. Various factors, which could be genomic or metabolic in 
nature, influence their etymology. Adverse drug reactions can also be classified as dose/drug-
induced reactions, allergic reactions, or idiosyncratic reactions.25-27 The existence of other diseases 
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and genetic factors are also risk factors modulating the occurrence of ADRs. The existence of other 
diseases or co-morbidities can result in an alteration of a particular pharmaceutical's 
pharmacokinetics.26 ADRs occur at a different rate depending on the concentration of various drug 
metabolites in circulation. In some instances, the drug metabolites are responsible for the ADRs 
observed.27  Pharmacokinetic properties of the pharmaceutical, its dosage, number of times it is 
administered, route of administration are also risk factors that modulate ADR occurrence.25,26 In 
addition, particular populations such as kidney or liver failure patients and geriatrics may have a 
propensity for increased ADR occurrence due to altered drug metabolism.25, 26 
It is almost axiomatic that all drugs, in addition to the desired ones, have the potential to produce 
undesirable effects.22 Pharmaceutical care warrants a good understanding of the risk factors and a 
tailored healthcare approach to meet the patient s needs. 
2.2.5 Challenges of Pharmacovigilance - Underreporting 
Pharmacovigilance in practice experiences various challenges, which include, underreporting of 
ADRs. This is a common and overwhelming problem.28-30  
A systematic review of 37 studies by Hazell and Shakir found a median under-reporting rate of 
94%.29 There are many factors, which contribute to the phenomenon of under-reporting of ADRs. 
Most nations, including South Africa, are primarily adopting the spontaneous or voluntary ADR 
reporting system. This system, although more affordable, presents various challenges. The issues 
include whether reporting practice is instilled in health care practitioners, the accuracy of reports, 
confusion as to whether a product has triggered a reaction or it is a different health condition 
presenting itself, time constraints hampering reporting, reporting liability problems, publication of 
reporting expectations and patient participation in reporting.31  
In addition, Terblanche et al. (2017), carried out a study in a South African public health hospital 
which reported that 53.8% of the healthcare professionals who participated gave not "knowing 
how to report" ADRs as the reason for not reporting.32 Ironically, this study has shown that some 
factors reported causing low ADR reporting rates and poor-quality reporting such as bad attitude 
and insufficient knowledge could be addressed.32 There are also patient-related reasons for 
underreporting like failure to recognize ADR or inability to link the ADR with a drug.30 
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An essential factor for drug safety is timely reporting of ADRs to drug regulatory bodies but under-
reporting is a major challenge. This is a universal concept affecting both developed and developing 
countries. This is despite developing countries having human and material resources to tackle the 
issue.31 
 
2.3 Pharmacoeconomics 
There is a growing realisation in the global community that resources are limited, and this concept 
applies to healthcare too. Various factors come into play in terms of healthcare financing. These 
include increasing rates of inflation and limited budgets. Due to this realisation, health care 
policymakers, over the last three decades, have had to appraise healthcare initiatives in terms of 
the benefits and costs. In order to be added onto various payers  formularies, new healthcare 
initiatives not only have to go through an economic evaluation but also have to be found 
economically beneficial.33 This phenomenon led to the birth of health economics and its sub-
branch, pharmacoeconomics. 
Pharmacoeconomics is defined as ''the description and analysis of the costs and consequences of 
pharmaceutical products and services and their impact on individuals, health care systems and 
society.''19 It is a field of economics that compares the costs and outcomes of various 
pharmaceutical products and treatment strategies.19 Therefore, pharmacoeconomic analyses are 
used to evaluate drugs for formulary status.  
Pharmacoeconomic concepts and methods have been in use since the early seventies.34 The trend 
in the use of pharmacoeconomics in formulary decision making, disease management programs as 
well as determining the cost-effectiveness of healthcare interventions is on the increase.  
2.3.1 Pharmacoeconomic Evaluations 
Economic evaluations allow for comparison between the costs and the benefits associated with a 
pharmaceutical.34 They take into consideration both costs and consequences to differentiate 
therapies.34, 35 
Costs are not limited to the price of a pharmaceutical but also societal effects such as loss of 
income, stress and time used to acquire medical help.36 The different types of healthcare costs 
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analysed include direct (medical and non-medical costs), indirect and intangible costs. 36 Benefits 
also vary from cure, quality-adjusted life-year (QALY) gained or income gained when healthy or 
well. 36 
Costs and benefits vary depending on the perspective of the analysis. The perspective of an 
economic evaluation is a statement of the point(s) of view from which the analysis is conducted. 
The analysis can have more than one perspective.37 Perspectives can be that of a payer, health care 
sector or societal.37 
2.3.2 Healthcare Costs and Financing 
According to a WHO report on global public health spending, in 2016, the world spent $7·5 trillion 
on health. There is an enormous disparity in per capita spending on health between developed and 
developing countries. Per capita spending on health in developed countries has been reported to 
be as high as $2000, versus only $100 to $400 developing coutries.38 In the absence of sustainable 
new health investment initiatives, rising health spending efficiency remains the backbone to 
achieving global health goals.  
Numerous reports detail the world s healthcare outlays.39-41 In 2018, the World Health 
Organization updated its global health outlays, up to 2016.39 The Organisation for Economic 
Cooperation and Development (OECD) has also released new data on official donor assistance for 
health in developing countries.40 Policy Cures Research released its latest g-finder survey in 
January 2019, monitoring global drug development expenses for neglected diseases up to 2017.41 
Schäferhoff et al. (2019) analysed these three data sources to establish patterns of healthcare 
funding. They also evaluated if the world is well on its way to mobilizing the funds required to 
achieve health objectives set out in the third sustainable development goal (SDG 3).39- 42 The 
analysis showed that healthcare outlays are rising. However, they remain inadequate for most 
governments of developing countries to finance universal health coverage, especially without 
donor funding.42  
In South Africa, the healthcare system is divided into two parallel systems, public and private 
sectors depending on the source of funding. The government, together with donors, is responsible 
for funding the public sector whilst profit and non –profit companies fund the private sector.43 
These tiers operate separately with little mixing. Previous papers have reported that the public 
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sector accounts for only 20% of healthcare spending in South Africa yet it is responsible for the 
health of 80% of the population. On the other hand, these reports note that the private sector 
accounts for 80% of healthcare spending on only 20% of the population.43 This gives a picture of 
how unequal access to health services in South Africa is. In order to address this inequity and also 
comply with the developmental goals of universal health coverage, South Africa has developed a 
framework for a National Healthcare Insurance. This is currently being piloted in 10 districts 
within the country.43 
2.3.2 Pharmacoeconomics in South Africa 
Implementation of pharmacoeconomics in South Africa has not been without its own challenges. 
Although the definition was adopted in 1996 in the National Drug Policy (NDP), the regulations 
allowing for the setting up of a pricing committee and the resulting Transparent Pricing System 
Regulations were only concluded and adopted in 2003 and 2004 respectively.34 The 
Pharmacoeconomic Guidelines were only developed almost a decade later in 2013.34 The aim of 
these was to provide guidance on conducting and submitting a pharmacoeconomic analysis. At 
present, pharmacoeconomic submission are voluntary with the plans of making them mandatory 
in future. 
2.4 Pharmacoeconomics of Adverse Drug Reactions 
Pharmacoeconomics applied to pharmacovigilance activities is an important aspect that helps to 
improve the rational use of medicinal products. ADRs increase patient morbidity and mortality 
and raise the overall cost of health.8 Through recording identified or suspected ADRs, health care 
providers and patients may assist in detecting patterns and trends. This is necessary for the 
regulatory oversight or removal from the market of products that may not have a favourable risk-
benefit ratio. 8 
Economic analyses supported data sources have shown that the entire cost of drug therapies is 
often much above the monetary price paid.42 When analysing the financial burden of 
pharmaceuticals, all costs and benefits must be taken into account. The benefits of a drug are 
expressed as the therapeutic effects shown in clinical trials. The risks include that they may cause 
adverse events, among other health implications.3  
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Various studies show that the costs of drug-related adverse events are significant.38-49 Depending 
on the perspective, the costs may vary substantially, according to the studies. Methodological 
differences such as the data sources for ADR, costs identification and methods of cost 
measurement result in varied costs reported.8 However, all these studies confirm that the costs of 
ADRs influence the outcome of a health economic analysis or pharmacoeconomic studies. 
Incremental cost estimates per ADR episode occurring in the hospitalized patients can range from 
$US1049.69 to $US5972.74.40-42 In non-hospitalized patients, the incremental cost estimate per 
ADR episode which results in hospitalization can range from $2427.45 to $5187.50.43-55There are 
limited studies on the cost of ADRs carried out in Africa. This could be due to limited resources, 
such as infrastructural, financial and skilled human resources.7 The studies carried out reported 
significantly lower costs compared to those reported on studies carried out in developed countries. 
This phenomenon can also be attributed to the limited resources, previously mentioned.56-58 
Akhideno et al. (2018) carried out a study on the economic burden, impact, and consequence of 
adverse drug reactions among medical inpatients in Nigeria. They found that the average cost of 
medications for treating ADRs among inpatients was $US24.38 per ADR episode. Throughout 
this research, it was confirmed that the central nervous system and the gastrointestinal system 
corresponding to the antidiabetic medication – insulin use causing neuroglycopenic symptoms and 
use of non-steroidal anti-inflammatory drugs (NSAIDs) causing NSAID-induced gastroenteritis / 
GIT bleeding, respectively – were the most frequently affected body systems by ADRs.57 
Schnippel et al. (2018) carried out a study on the direct costs of managing adverse drug reactions 
during rifampicin-resistant tuberculosis treatment in South Africa. They estimated that the 
incremental costs of ADR management were US$380.17 annually per patient initiating on multi-
drug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The 
incremental costs of ADR management for the public health sector in South Africa were US$4.76 
million, 8.3% of the estimated cohort costs of MDR/RR-TB treatment ($57.55 million) for the 
2015 cohort of 12 527 patients.58 The link between pharmacoeconomics and pharmacovigilance 
allows future and current ADRs to be monetized and budgeted for. This will also allow for better 
planning and cost savings for the institutions or patients involved. 
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2.5 Mini Scoping Review on Incidence and Types of ADRs to HAART  
In an effort to review available information on incidence and types of ADR to HAART, a mini- 
scoping review was conducted. Specific review techniques and methodology as outlined by Levac 
et al. (2010) were applied.59 This guided the development of a search strategy and criteria to 
identify and appraise articles that focused on economic evaluations as well as incidence reports on 
adverse drug reactions attributable to Highly Active Anti-Retroviral Therapy. All studies identified 
were used the analysis. The data from studies included in the scoping review were extracted and 
summarised in Table 1. The data extracted included general information about the article (source, 
author and year of publication of each article), as well as information on the study design and study 
outcome measures. 
Many studies have been carried out on the incidence and risk factors of HAART induced ADRs.60-
69 These studies have shown that ADRs to HAART are common causes of morbidity, change in 
treatment and even mortality. ADRs to HAART vary in severity and duration. The main events 
associated with the use of antiretroviral medicinal products include altered psychosis, body fat 
distribution (lipodystrophy), altered sleep patterns, anaemia and neutropenia, hypersensitivity 
reactions, hepatic disorders, altered bone structure (osteopenia and osteoporosis), muscle damage 
(myopathy), acute pancreatitis, nausea, diarrhoea and lactic acidosis.70-79
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Author 
Country, 
Year 
Data Source 
Study Design ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Chowta et al. 
India, 2018 
  
  
Google 
Scholar 
  
  
  
  
  
  
  
  
  
Prospective 
observational  
  
  
  
  
  
  
  
  
  
  
  
  
Haemoglobin or absolute 
anaemia 
zidovudine 26 15,2% 
Nonspecific feeling of being 
unwell 
tenofovir 1 0,6% 
Lactic acidosis stavudine 3 1,8% 
 Peripheral neuropathy stavudine 2 1,2% 
Pancreatitis stavudine 1 0,6% 
Dyslipidaemia stavudine 2 1,2% 
Lipoatrophy   1 0,6% 
Nausea   28 16,4% 
GI Intolerance   17 9,9% 
Hepatoxicity   14 8,2% 
Rash and Itching nevirapine 26 15,2% 
Neutropenia   9 5,3% 
Thrombocytopenia   8 4,7% 
Headache and Insomnia   2 1,2% 
Table 2.1: Studies on the Incidence of ADRs to HAART  
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Author 
Country, 
Year 
Data Source 
Study Design ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Yang et al. 
International 
Journal of 
Infectious 
Diseases 
China, 2019 
 
Retrospective observational 
  
 
Decrease in GFR rate 
  
  
Tenofovir 
 TDF regimens showed a better plasma lipid 
profile but mild renal dysfunction as compared 
to non-TDF based regimens. Patients with high 
BMI, high baseline TG, high baseline TCH and 
low baseline eGFR should be closely 
monitored when using TDF-based ART. 
Luma et al. 
Cameroon, 
2012 
  
  
Pubmed 
  
  
  
Cross sectional clinical chart 
review 
  
  
  
  
  
  
  
Peripheral neuropathy   15 4% 
CNS ADRs   12 4% 
GIT ADRs   12 4% 
Skin reactions   7 2% 
Lipid system reactions   6 2% 
Haemoglobin or absolute 
anaemia 
  7 2% 
Nonspecific feeling of being 
unwell 
  4 1% 
Lactic acidosis   3 1% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Author 
Country, Year 
Data Source 
Study Design ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Lorio et al. 
Nicaragua,2014  
  
Google Scholar 
  
Retrospective, 
observational 
  
  
  
  
CNS related   
  
  
  
  
  
20 2,9% 
GI related 12 1,7% 
Dermatologic 8 1,2% 
Heamatologic 3 0,4% 
Renal 1 0,1% 
Endocrine 1 0,1% 
Agada et al. 
Nigeria, 2016 
  
Google Scholar 
  
  
  
  
Cross-sectional 
retrospective 
  
  
  
  
  
  
  
CNS related   
  
  
  
  
  
  
  
42 36,2% 
GI related 48 41,4% 
Dermatologic 4 3,4% 
Heamatologic 13 11,2% 
Renal 4 3,4% 
Endocrine 3 2,6% 
Cardiovascular 15 12,9% 
Musculoskeletal system  39 33,6% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Author 
Country, 
Year 
Data Source 
STUDY 
DESIGN 
ADRs identified Drug Related to 
ADR  
Number of 
cases 
Incidence 
Eluwa et al. 
Nigeria,2012 
  
Google 
Scholar 
  
  
  
  
  
  
  
  
Central and Peripheral NS 
related 
  
  
  
  
  
  
37 1,4% 
GI related 9 0,3% 
Dermatologic 26 1,0% 
Cardiovascular 2 0,1% 
Systemic Symptoms 3 0,1% 
Musculoskeletal 1 0,0% 
Mudzviti et 
al. 
Zimbabwe, 
2015 
  
Pubmed 
  
Retrospective 
patient  
medical  
records 
review 
  
Generalised skin rash   
  
  
  
  
13 5,9% 
Papular rash 6 2,7% 
Erythematous rash 3 1,4% 
Stevens- Johnson syndrome 2 0,9% 
urticarial reaction 1 0,5% 
Raikar et al. 
India, 2018 
  
Google 
Scholar 
  
Retrospective 
  
  
  
  
Gastrointestinal system    
  
  
  
  
36 12% 
Dermatology  33 11% 
Central nervous system  19 7% 
Musculoskeletal system  10 3% 
Others  15 5% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Author 
Country, Year 
Data Source 
Study Design ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Ndangije et al. 
Uganda,2015 
  
  
Reference list 
  
  
  
  
Prospective  
cohort study 
  
  
  
  
  
  
  
Increased creatinine ([1.2 g/dL)  tenofovir 43 0,42% 
Creatinine clearance[90 mL/min  43 0,42% 
Creatinine levels not provided  10 0,10% 
Proteinuria 25 0,24% 
Glycosuria and proteinuria  11 0,11% 
Bone demineralization  5 0,05% 
Bilateral pitting pedal oedema  6 0,06% 
Facial puffiness  4 0,04% 
Renal Toxicity 53 0,52% 
Singh et al 
India, 2016 
  
  
  
Google Scholar 
  
  
  
  
  
Prospective  
cross sectional 
observational 
study 
  
  
  
  
  
  
  
Hematological    
  
  
  
  
  
  
  
  
  
  
50 8,4% 
Gastrointestinal  39 6,6% 
Cutaneous  35 5,9% 
Neurological  16 2,7% 
Musculoskeletal  15 2,5% 
Metabolic 8 1,3% 
Cardiovascular  6 1,0% 
Hepatic toxicity  4 0,7% 
Psychiatric disorders  3 0,5% 
IRIS  2 0,3% 
Others  10 1,7% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Author 
Country, 
Year 
Data Source 
Study 
Design 
ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Sadiq et al. 
India, 2016 
  
  
Google 
Scholar 
  
  
  
  
  
  
  
  
Prospective  
observational 
study 
  
  
  
  
  
  
  
  
  
  
Anemia    14 16% 
Gastritis    14 16% 
Vomiting    13 14% 
Rashes    12 13% 
Loss of appetite    10 11% 
Sedation    9 10% 
Lipodystrophy   9 10% 
Oesophageal candidiasis    7 8% 
Diarrhoea    6 7% 
Giddiness    5 6% 
Hepatic dysfunction    6 7% 
Peripheral neuropathy    3 3% 
Fever    1 1% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Author 
Country, 
Year 
Data Source 
Study 
Design 
ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Kumar et al. 
India, 2017 
  
  
Pubmed 
  
  
  
  
  
  
  
Retrospective 
  
  
  
  
  
  
  
  
  
  
  
Red blood cell disorder    326 29,10% 
Metabolic and nutritional 
disorder 
  83 7,41% 
Central and peripheral nervous 
system 
  119 10,62% 
Gastrointestinal system 
disorders  
  221 19,73% 
Liver and biliary system 
disorder  
  57 5,08% 
Psychiatric Disorders   24 2,14% 
Skin and appendages disorders    119 10,62% 
Urinary system disorders    24 2,14% 
White cell and RES disorders    13 1,21% 
Body pain whole    8 0,71% 
Resistance Mechanism disorder    104 9,28% 
Musculo-Skeletal disorder    22 1,96% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Author 
Country, 
Year 
Data Source 
Study 
Design 
ADRs Identified Drug Related to 
ADR  
Number of 
Cases 
Incidence 
Divaka et al. 
India,2012 
  
  
  
Google 
Scholar 
  
  
  
  
  
  
  
Prospective  
cohort study 
  
  
  
  
  
  
  
  
  
  
  
Aneamia   
  
  
  
  
  
  
  
  
  
  
  
  
26 6,50% 
Nausea 12 3,00% 
Gastritis 5 1,25% 
Rash 25 6,25% 
Vomiting 9 2,25% 
Itching 9 2,25% 
Headache 2 0,50% 
Peripheral Neuropathy 4 1,00% 
S.J.S 4 1,00% 
Anorexia 5 1,25% 
Insomnia 1 0,25% 
Stomatitis 1 0,25% 
Body ache 4 1,00% 
Table 2.1: Studies on the Incidence of ADRs to HAART cont. 
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Incidence data from the studies in Table 1 was extracted on to Microsoft Excel and analysed. 
(Table 2.2). Data on 4404 patients was extracted from the studies included in the literature review 
analysis. 34% of the patients in the analysis experienced at least one ADR to HAART.  
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Chowta et al. 171 4 45 26 43 0 4 0 1 3 0 
Radhakrishnan et al. 110 8 11 5 17 2 4 0 0 2 7 
Luma et al. 339 27 12 7 7  0 9 0 0 4  0 
Lorio et al. 692 20 12 8 3 1 1 0 0 0  0 
Eluwa et al. 265 37 9 26 3 0 0 2 1 0  0 
Sadiq et al. 90 9 40 9 10 0 5  0 3 0 4 
Raikar et al. 289 19 36 33 15 0 0 0 10 0 0 
Mudzviti et al. 221 0 0 25 0 0  0 0 0 0 0 
Singh et al. 595 19 39 12 50 0 8 6 0 0 4 
Kumar et al. 1400 69 107 57 220 12 40  0 11 54 27 
Adaga et al. 232 42 48 4 13 4 3 15 39 0 0 
Total number of 
patients 
4404 254 358 212 381 19 74 23 64 63 43 
Table 2.2: ADR occurrence frequency analysed 
The reported ADRs associated with the use of ARVs were Haematological (n=381,8.65% ),GI 
related (n=358, 8.13%), CNS related (n=254, 5.77%), Dermatologic (n=212, 4.81%), Renal (n=19, 
0.42%), Endocrine related (n=74, 1.68%), Musculoskeletal related (n=64, 1.46%), Systemic 
(n=63, 1.43%), Hepatic (n=43, 0.97%) and Cardiovascular (n=43, 0.52%). (Fig 1) 
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FIG 2.1: Boxplot showing the measure of spread of the various ADRs 
This literature review aimed to analyse the data available on ADRs to HAART in terms of 
incidence of ADRs. Studies from developing countries were collated and analysis on ADR 
incidence was carried out. The incidence of ADRs to HAART reported in the collated analysis 
was 34%. This lies within the range seen in the literature reviewed. 
The studies reviewed on incidence were carried out in developing countries mostly. This was 
important, as there tend to be significant differences in the psychological and socioeconomic 
support of HIV positive patients in comparison to developed countries.  Public health sectors of 
developing countries experience challenges such as co-morbidities and malnutrition that confound 
the incidence of ADRs.63 In addition, constraint resources result in limited laboratory testing which 
inhibits prompt and accurate diagnosis of toxicities. Use of herbal medicines as well as the high 
prevalence of opportunistic infections are also factors that allude to increased incidence of some 
of the ADRs due to drug-interactions. 71 Host biology or genetics are associated with differences 
in the pharmacokinetics and metabolism of the pharmaceutical. This alters the body s response 
leading to varied observed drug toxicity.71 
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2.6 Costs of HAART in South Africa  
In South Africa, the national government funds the bulk of the national HIV program. According 
to the 2019 budget, this program receives a significant portion of the total grant allocation. This is 
in a bid to continue the implementation of the universal test-and-treat policy for antiretroviral 
treatment and to provide services intended to prevent the spread of HIV. It received in excess of 
R25billion per annum.80 HAART is the major cost contributor to implementing HIV programs. It 
contributes between 56% and 77% of the total costs of HIV programs in South Africa.81 
South Africa National Treatment guidelines adopt and are in line with the WHO's treatment 
guidelines. The various HAART regimens differ in costs as well as effectiveness.  
Bendavid et al. (2011) adopted a mathematical simulation model of the progression of HIV/AIDS 
to determine the cost-effectiveness of various antiretroviral regimens that constitute the World 
Health Organization's Treatment Guidelines. In this study, they analysed 5 treatment regiments 
namely: 
1. Tenofovir + lamivudine + efavirenz (TDF/3TC/EFV);  
2. Tenofovir + lamivudine + nevirapine (TDF/3TC/NVP); 
3. Stavudine + lamivudine + nevirapine (d4T/3TC/NVP; 
4. Zidovudine + lamivudine + efavirenz (AZT/3TC/EFV); and 
5. Zidovudine + lamivudine + nevirapine (AZT/3TC/NVP).77 
They used the model to determine the annual direct cost incurred in patients that remained in care. 
The following assumptions were adopted for modelling, amongst others: 
1. The patients presented when already ill and treatment was initiated immediately (during this 
era, patients had to wait until CD4 count dropped to 350 or below before HAART was initiated). 
 
29 
 
2. Co-morbidities, its toxicities and the incidence rates of these two affect the effectiveness of 
HAART. 
3. All patients have access to CD4 monitoring at treatment initiation as well as during treatment. 
Cost-effectiveness was determined as the ability of the regimen to decrease the viral load and 
therefore decrease mortality. They found that annual costs for patients on HAART and remaining 
in care ranged between US$810 and US$1713. Three HAART treatment regiments, namely, 
TDF/3TC/EFV; TDF/3TC/NVP and AZT/3TC/EFV, were found to be cost-effective. 
D4T/3TC/NVP was found to be the most expensive whilst AZT/3TC/NVP was the least effective. 
These findings were in line with current WHO HAART guidelines82 
2.6 Costs of ADRS associated with HAART 
There are limited studies on the costs of ADRs associated with HAART compared to those of the 
incidence of the ADRs. Despite this, the studies analysed all show that costs associated with ADR 
are significant. Table 2.3 summarises the studies carries out on the costs associated with HAART 
adverse drug reactions.  
Homar et al. (2012) carried out a study comparing healthcare costs for patients on fixed-dose 
combinations (FDCs) of antiretroviral agents compared to separate individual antiretroviral agents. 
The study was carried out in the Belearic Islands, Spain using a hospital inpatients database. The 
costs analysed were consultations with health professionals, admission/ward costs, procedures 
(e.g. liver biopsy, colonoscopy, ultrasounds) and laboratory studies (e.g. urinalysis, viral load, 
lymphocyte subpopulation studies, liver profile, coagulation profile). They found that patients on 
separated individual antiretroviral agents had higher healthcare costs compared to fixed-dose 
combination antiretroviral.83
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Author 
Country, 
Year Data 
Source 
Study Design ADRs 
Identified 
Drug Related 
to ADR as 
Observed 
Number 
of Cases 
Incidence Perspective Cost 
(US$) 
Cost 
Description 
Conclusion 
Radhakrishnan 
et al 
India, 2017 
  
Google 
Scholar 
  
  
  
  
  
  
  
  
  
Retrospective, 
observational 
  
Aneamia Zidovudine 15 13,6% Payer 15,5 Laboratory 
costs, 
treatment 
costs, 
hospital 
stay costs 
Overall 
direct costs 
associated 
with 
treating 
ADRs to 
HAART 
was found 
to be high, 
thus 
increasing 
the overall 
cost of HIV 
therapy 
Nausea & 
vomiting 
Zidovudine 7 6,4%   18 
  Hepatoxicity Nevirapine 7 6,4%   17,45 
  Peripheral 
neuropathy 
Stavudine 6 5,5%   14,7 
  Pancreatitis Stavudine 4 3,6%   141,9 
  Rash Efavirenz 3 2,7%   45,8 
  Stevens–
Johnson  
 
Syndrome 
(sjs) 
Nevirapine 2 1,8%   208,5 
  Renal failure Tenofovir 2 1,8%   120,8 
  Depression Efavirenz 2 1,8%   215,3 
  Pancytopenia Zidovudine 2 1,8%   108,3 
  Diarrhea Ritonavir 2 1,8%   83,1 
  Gastritis Efavirenz 2 1,8%   59,3 
  Fever Zidovudine 2 1,8%   36,6 
Table 2.3: Economic Evaluations on the management of ADRs to HAART 
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Author Country, Year 
Data Source 
Study Design ADRs identified Number of 
cases 
Perspective Cost (US$) 
Cost 
Description 
Conclusion 
Simpson et al Cross-sectional 
retrospective 
CNS related 427 Payer 
Of the 2548 NNRTI-treated patients, 29.3% 
experienced AEs. During the 12 months 
following NNRTI initiation, the mean annual 
total health care cost was $27 299 (efavirenz: 
$26 185; other NNRTIs: $34 993) and AE-
associate costs were $608 (efavirenz: $554; 
other NNRTIs: $979) among all NNRTI 
users. 
USA, 2014   GI related 146   
    Dermatologic 93   
    Lipid Disorders 312   
Pubmed   Hepatoxicity 55   
Dekoven et al retrospective case–
control database study 
  
Depression 173 Payer Differences in median total all-cause health 
care costs observed for diabetes/insulin 
resistance management (US$14 547 median 
all-cause health care costs during time 
periods identified as diabetes/insulin 
resistance medical events versus US$11 237 
without diabetes/insulin resistance events; P 
<0.05 .0021), lipid disorders (US$12 825 
versus US$10 033; P<0.05 .0004), and renal 
disorders (US$1389 versus US$0; P < .0001. 
This study concluded that health care costs of 
ART AEs should be key consideration for 
payers/providers in HIV management. 
USA,2015 Diabetes/Insulin 
resistance  
115   
    Diarrhea  181   
    Dizziness  69   
Google   Hepatic disorders 38   
    Lipid disorders  497   
    Nausea/vomiting 132   
    Rash  228   
    Renal disorders  93   
    Somnolence/sleep 
effects 
317   
Table 2.3: Economic Evaluations on the management of ADRs to HAART cont.
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Radhakrishnan et al. (2012) carried out a study in a tertiary care teaching hospital in Southern 
India. The study aimed to analyse the direct costs of ADRs to HAART in HIV/AIDS patients. 
Costs analysed included hospital stay costs, pharmacy (drugs) cost and laboratory 
investigations costs. In their study incidence of ADRs due to HAART was 50.9%, the majority 
of ADRs to HAART, causality assessment was 'probable', and 'possible' by WHO probability 
scale. Based on the modified Hart wig and Siegel scale, of the 56 observed ADRs, 6 were mild 
(10.7%), 42 were moderate (75%) and 8 were severe (14.3%). The direct cost incurred in 
managing ADRs to HAART reported was INR 72428(US$ 1574.51). They reported increased 
costs associated with ADRs as severity increased. The total mean direct cost seems less in a 
developing country like India, compared to developed countries like the United States where 
the direct cost incurred in treating ADRs to HAART ranges to several thousand dollars. 
However, when compared the per capita spending on health in India, this cost associated with 
ADRs is significantly high.15 
Dekoven et al. (2016) carried out a study to estimate health care costs associated with medical 
events identified as HAART-attributable ADRs. The study was carried out in the United States 
of America (USA) using a pharmaceutical claims database. The ADRs analysed in this study 
were depression, dizziness, diarrhoea, hepatic disorders, nausea/vomiting, rash, renal disorders, 
and somnolence/sleep effects, diabetes/insulin resistance and lipid disorders. Pharmacy costs 
analysed included costs of ART as well as costs of medications associated with the treatment 
of the ADRs. Their analysis showed that pharmacy costs had the highest attributable costs. 
They observed that costs attributable to ADRs analysed were in excess of US$23434 for the 
study. This confirms that costs associated with treatment or prevention of HAART ADRs are 
a primary factor to be considered in HIV control for the payers/providers.12 
Johnston et al. (2013) carried out a retrospective study to compare the incidence and healthcare 
costs of medically attended adverse effects in atazanavir-and darunavir-based antiretroviral 
therapy among U.S. Medicaid patients receiving routine HIV care. This study analysed in-
patient, outpatient and pharmacy costs. They found that the total healthcare costs attributable 
to ADRs were $8127 for the duration of the study. This amount is significant and should be 
considered when analysing the cost of HAART.13 
Simpson et al. (2014) carried out a study to assess the incidence and costs of ADRs among 
patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) from the health care system perspective. They enrolled 2548 NNRTI-treated patients 
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over a period of 5 years. ADRs observed were rash, nausea or vomiting, diarrhoea, dizziness, 
headache, sleep-related symptoms, hepatotoxicity, lipid disorder, depression, anxiety, and 
suicide or self-injury. A total of  29.3% of the study participants experienced ADRs. The mean 
incremental costs per episode from US$1580 to US$12 833.14 
Irrespective of the different settings in which the above studies were conducted, they all agree 
that the cost of managing ADRs attributed to HAART is significantly high. Most of the studies 
reviewed were carried out in high-income settings. In resource-limited settings, the cost of 
managing these ADRs is relatively unknown and hence not factored into budget estimations. 
This warrants the need to analyse these costs at a local level.  
2.7 Chapter Summary 
This chapter summarizes the literature review on the pharmacovigilance of HAART as well 
as the costs associated adverse drug reactions of HAART.  
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ABSTRACT 
 
Objective 
The aim of the study is to identify adverse drug reactions attributable to tenofovir- and 
zidovudine-based fixed-dose combinations of highly active anti-retroviral therapy and, 
subsequently, to determine the annual costs incurred managing these adverse drug reactions 
and the budget implications of this at an outpatient anti-retroviral clinic in Mamelodi, Pretoria.  
Methods  
This retrospective cohort study reviewed de-identified clinical data for adverse drug reactions. 
Medical charts of HIV-positive patients, who were on either tenofovir- or zidovudine-based 
fixed-dose combinations of anti-retroviral therapy, were analysed. Based on the costs and the 
incidence rates of adverse drug reactions observed in the analysis, a decision tree model was 
established to estimate the cost impact of adverse drug reaction management on the clinic s 
budget.  
Results  
A total of 469 patient files were analysed (62% female vs 38% male). The mean age at the start 
of anti-retroviral therapy for the cohort was 36.6yrs (95% CI 35.74-37.45) and  the mean 
baseline CD4 count was 380 (95% CI 343-418). Incidence of adverse drug reactions to 
tenofovir- or zidovudine-based fixed-dose combinations of anti-retroviral therapy was found 
to be 24.95%. The ADRs reported with the use of TDF and AZT based HAART regimens were 
rash  (n=45, 27%), decreased glomerular filtration rate (n=34, 21%), trouble sleeping (n=39, 
21%), severe diarrhoea (n=19, 12%), nausea and vomitting (n=18, 11%), decreased 
heamoglobin or anaemia (n=4, 2%), headaches (n=4, 2%), dizziness (n=2, 5.3%).  
 
The study revealed that ZAR427.30 was the cost attributed to adverse drug reactions due to 
tenofovir-based regimens whilst ZAR467.94 was the cost attributed to adverse drug reactions 
due to zidovudine-based regimens, per patient, during the first year of treatment. Costs 
attributed to gastro-intestinal related adverse drug reactions were the highest in comparison to 
other adverse drug reactions. Estimated total cost of adverse drug reactions attributed to 
zidovudine-based therapy was ZAR8003.98 (US$556.40) and estimated total cost of adverse 
drug reactions attributed to tenofovir-based anti-retroviral therapy per annum was ZAR33 788, 
23 (US$2348.80) for 1221patients initiated on antiretroviral therapy between July 2017 and 
June 2018 at the clinic.  
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Conclusion  
Despite our estimated costs to the clinic, due to adverse drug reactions, being lower than similar 
studies, there remains a notable budget impact on a resource-limited setting. These estimates 
will allow for cost due to adverse drug reactions caused by tenofovir- and zidovudine-based 
anti-retroviral therapy to be accounted for in budgets at the Anti-Retroviral clinic.  
 
Keywords: Adverse drug reactions, cost analysis, highly active anti-retroviral therapy, 
tenofovir, zidovudine. 
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Introduction 
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) 
remain the greatest public health crisis in the world today and is the fourth leading cause of 
mortality in the world.1 The concern is not only a major public health issue, but also a socio-
economic and developmental crisis that affects all sectors of the population.2  
 
According to the UNAIDS statistics, in 2018 7.7 million people in South Africa were HIV-
positive.1 This makes South Africa home to the largest number of HIV positive people 
worldwide. In addition, South Africa has the largest Antiretroviral Therapy (ART) program in 
the world. In 2018, more than 4.5 million people were receiving ART, which equates to 62% 
of people living with HIV in the country.1 These statistics show that there are still several 
interventions required to minimise the effects of HIV/AIDS. 
 
Highly Active Anti-Retroviral Therapy (HAART), a combination therapy of three or more anti-
retroviral drugs, has significantly improved the health outcomes of the infected population, 
making HIV a manageable disease. It has reduced morbidity and mortality in HIV-positive 
patients significantly. Without therapy, probably more than 90% of all HIV-positive patients 
will die from AIDS.3 The increase in life expectancy of HIV-positive patients on HAART also 
means increased duration on treatment as well as increased incidence of common, as well as 
rare adverse drug reactions (ADRs). Cost of managing and treating the ADRs become 
significant as nations try to meet the 90-90-90 target set by UNAIDS. This target aims that by 
2020, 90% of all HIV-infected individuals be diagnosed, 90% of patients with a diagnosis to 
have initiated treatment and 90% of those who have initiated treatment to be virally 
suppressed.1 
 
Zidovudine (AZT) and tenofovir (TDF) (non-nucleoside reverse transcriptase inhibitors 
(NNRTI)) form the backbone of first-line antiretroviral therapy as per the World Health 
Organization s guidelines.4 Studies have been carried out to compare the TDF and AZT 
regimens for efficacy and cost-effectiveness.5,6,7,8,9 One such prospective study, conducted in 
South Africa, compared the efficacy of  TDF-based HAART vs AZT-based HAART 
regimens.5 This was done by comparing the ability of the HAART regimens to reduce viral 
loads to undetectable levels as well as comparing the rate of need for drug substitutions. The 
results indicated that fixed-dose TDF-based HAART had superior efficacy in terms of 
decreasing viral load to undetectable levels compared to fixed-dose AZT-based HAART. It 
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also had the least regimen substitutions recorded.5  Likewise, other studies have also shown that 
TDF-based HAART was superior to AZT-based HAART in achieving an undetectable viral 
load and increasing CD4 levels.6, 7, 8 In contrast, large randomized clinical trials carried out in 
different countries found no significant difference in virological suppression between TDF and 
AZT treatment groups.9 Other studies in South Africa and Indonesia also found no significant 
differences in terms of regimen switches and virological suppression between patients on TDF- 
based HAART vs AZT-based HAART.10,11  Studies comparing cost effectiveness of TDF- and 
AZT-based HAART have generally found TDF-based HAART regimens more cost effective 
than AZT-based regimens.12,13  
 
Many studies have been carried out on the incidence and risk factors of HAART induced 
ADRs.14-20 There are however, limited studies looking into the costs associated with the 
management of the ADRs.  In resource-limited settings, the cost of managing these ADRs is 
relatively unknown and hence not factored into budget estimations.  
 
An adverse drug reaction is defined as ‘a response to a drug which is noxious and unintended, 
and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of 
disease, or for the modifications of physiological function. 3 ADRs are common causes of 
morbidity and mortality as well as a significant contributor to increased healthcare costs. In 
order to understand the impact of ADRs on healthcare costs, all costs and benefits have to be 
taken into account. ADRs are associated with two main inversely correlated costs, i.e. the cost 
of treating diseases due to ADRs and the cost of evading them. When one arm increases, the 
other decreases.14 
 
Based on the review and literature search, it was found that there were limited studies analysing 
the cost of management and prevention of ADRs attributed to HAART in South Africa. The 
consideration of the healthcare costs of ADRs is paramount in understanding the total impact 
on the cost of managing HIV as well as the value of HAART.  The aim of the study is to 
identify adverse drug reactions attributable to tenofovir- and zidovudine-based fixed-dose 
combinations of highly active anti-retroviral therapy and, subsequently, to determine the annual 
costs incurred managing these adverse drug reactions and the budget implications of this in an 
outpatient anti-retroviral clinic in Gauteng. 
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Methods 
Study Setting and Population 
Study was carried out at a Community Health Center, in Mamelodi, Pretoria.  The Community 
Health Center caters for all types of primary healthcare services, including an ARV clinic. 
 
Ethical approval 
Permission to conduct the study was obtained from the Biomedical Research Ethics Review 
Committee of the University of KwaZulu-Natal (BE404/17) and gatekeeper approval was 
obtained from the Gauteng Department of Health, Tshwane Research Committe  (PROJECT # 
61/2018, NHRD REF GP_201805_034). Confidentiality was duly maintained, and basic 
prnciples of research ethics were  adhered to. 
 
Sampling and data collection 
The study was a retrospective cohort study. De-identified clinical information and laboratory 
data of adult patients who started on HAART between July 2017 and June 2018 was analysed. 
The clinic utilises an electronic system called the Tier System to capture and store patients  
medical information. Medical history previously captured on the Tier System was retrieved to 
fulfil the aims of the study.  
 
Inclusion/Exclusion criteria 
The following inclusion/exclusion criteria was used to enrol patients into the study. Patients 
were included if they were at least 18 years old, HIV- positive and on HAART. Patients were 
required to be on either a tenofovir- or zidovudine-based fixed-dose combination HAART for 
at least 12 months continuously at the time of enrolment. They needed to have been initiated 
on either a tenofovir- or zidovudine-based fixed-dose combination HAART between June 2017 
and June 2018. Exclusion criteria encompassed having co-morbidities such as hepatitis, 
tuberculosis (TB), diabetes or cardiovascular diseases. Patients were also excluded if there was 
incomplete data recorded on their medical charts.  
 
Causality and Severity  
At the Clinic, ADRs are documented as part of the observation and treatment plan. There is no 
causality confirmed on the medical charts or on the Tier system. Events of interest for this 
study included documented ADRs. The WHO Causality Assessment Tool was used to ascertain 
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causality and severity of the ADRs. 21 This tool details criteria used to evaluate the causal 
association between ADRs and the pharmaceuticals in question. The categories used are 
unassessable/unclassifiable, conditional/unclassified, unlikely, possible, probable/likely and 
certain in order of certainty.21 
 
Severity of adverse reactions was assessed using the Hartwig scale and classified as mild, 
moderate and severe.22 According to the Hartwig scale, ‘ADRs are considered severe if patient 
outcomes fall in category permanent harm, lead to death and required any intensive medical 
care admission due to an ADR. ADRs are considered moderate if withdrawal of suspected drug 
therapy is required, needing antidote, and lead to increase in the hospital stay or reason for 
admission. Finally, ADRs are classified as mild if it does not require any change in the 
treatment or not requiring an antidote. 22 
 
Statistical Analysis 
The data, obtained from electronic patient medical records, was transcribed onto  Microsoft 
Office Excel® spreadsheets. Data obtained included patient s date of birth, gender, HIV 
diagnosis date, date of HAART start, stage at ART start, baseline viral load count, last viral 
load result and date, baseline creatinine level, creatinine level, baseline CD4, latest CD4 count, 
full blood count dates, last HAART visit dates, pregnancy status on ART start, treatment notes, 
ADR reported and the HAART regimen that was involved. Patients were separated into 2 
groups i.e case and control. Case groups were those patients that recorded an ADR, while the 
control group included patients not experiencing any ADR. The 2 groups were compared for 
age at HAART initiation, baseline CD4, total HAART costs, total laboratory costs and total 
direct costs using the independent sample t-test. 
 
Cost Analysis 
Direct cost associated with TDF- and AZT-based HAART were analysed. Direct medical costs 
are those costs incurred for medical products and services used to prevent, detect, and/or treat 
a disease. Costs incurred (laboratory charges and pharmaceutical charges) were extracted from 
the Clinic s accounting system as well as its suppliers such as National Health Laboratory 
Services billing system (Table 1). 
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Input Parameters 
Input Unit costs of resources used (South 
African Rand-ZAR) 
Laboratory Tests  
HIV Viral Load R1200.90 
CD4 count R300.50 
Creatinine Level Test R51.70 
Full Blood Count (FBC) R50.06 
Pharmaceuticals Dispensed  
Tenofovir/Lamivudine/Efavirenz 
(TDF/3TC/EFV) 28s 
R105.08 
Tenofovir/Emtricitabine/Efavirenz 
(TDF/FTC/EFV) 28s 
R125.21 
Zidovudine/Lamivudine 28s R56.00 
Nevirapine tablets R39.00 
Efavirenz 28s R42.00 
Loperamide tablets R1.80 
Ferrous Sulphate tablets 28s R4.68 
Trepiline 25mg tablets 28s R3.10 
Allergex 4mg tablets R1.14 
Allercet 10mg tablets  R2.72 
Biocort Cream R6.80 
Table 3.1: Input Parameters 
 
Perspective 
The payer s perspective was used for this analysis. The study was carried out at a provincial 
clinic therefore the Gauteng Health Department is the payer in this analysis.  
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Budget Impact Analysis 
A decision tree model was established to estimate the impact of costs of ADR management on 
the clinic s budget. This estimate was for the number of patients initiated on TDF and AZT 
based HAART during the year of analysis, which was 1221 patients. Based on the data 
collected, and the results from the above analysis, a novel budget impact model was built in 
Microsoft® Excel®. The model simulated the natural occurrence and progression of observed 
ADRs to TDF- and AZT-based HAART.  It starts at initiation of TDF- or AZT-based HAART 
where patients in a state of absence of ADRs. From being in a state of absence of ADRs, 
patients can progress to the development of an ADR state or stay in a state absence of ADRs. 
In the event that patients develop an ADR, they are treated, which leads to either cure or non-
cure (ADR not resolved). When cured, the patient returns to a state of absence of ADRs. 
 
Studies have shown that most ADRs caused by HAART occur within the first year of 
treatment.23,24 Therefore, the consequences and associated healthcare expenditure are 
assessable in a short-term period.  The time horizon was set to one year, in line with the data 
collected and analysed.  
 
Sensitivity Analysis 
In order to address the uncertainty, a two-way sensitivity analysis was carried out. Mean costs 
attributable to ADRs as well as ADR incidence were the variables. The lower and upper bound 
for the 95% confidence interval for the mean cost attributable to ADRs was utilised to observe 
how the model outputs change as the inputs are changed. TDF-based HAART and AZT-based 
HAART ADR incidences were derived from literature and utilised in the two-way sensitivity 
analysis. AZT-based HAART ADR incidences utilised were 0.052 17, 0.084 25 and 0.244 19. 
TDF-based HAART ADR incidences utilised were 0.0196 26 0.084 25 and 0.39 27.  
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Results 
Sampling and Overview of participant demographics 
Figure 1 below details how the inclusion-exclusion criteria was utilised and how the study 
sample was derived.  
 
 
Fig 3.1: Sampling Flow Chart 
In this study, 469 patients charts were eligible for analysis. In this study, 469 patient-charts 
were eligible for analysis. The mean age at the start of HAART for the cohort was 36.6yrs 
(95% CI 35.74-37.45); the mean baseline CD4 count was 380 (95% CI 343-418). 62% of the 
patients analysed were female. 454 patients (96,8%) on TDF based HAART, whilst only 15 
patients (3.2%) were on AZT based HAART. The patients breakdown according to regimens:  
1. Tenofovir + emtricitabine + efavirenz (n=448); 
2. Tenofovir + lamivudine + efavirenz (n=6); 
3. Zidovudine + lamivudine + efavirenz(n=12); and 
4. Zidovudine + lamivudine + nevirapine(n=3). 
These patients were grouped according to ADR status (present or absent). Patients  who 
presented with ADRs to TDF or AZT based HAART and those who had not experienced an 
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ADR with  TDF or AZT based HAART were compared with independent t-test for gender, 
age, and CD4 count at HAART initiation. 
 
  ADR Present ADR Absent 
TDF Based 
Regimen 
AZT Based 
Regimen 
TDF Based 
Regimen 
AZT Based 
Regimen 
Gender         
Female 65 8 215 3 
Male 42 2 132 2 
Age         
18-30 37 4 82 2 
31-40 40 6 149 3 
41-50 28   87   
51-60 2 0 21 0 
>60 0 0 8 0 
CD4         
<350 60 7 115 4 
≥350 47 3 232 1 
 
Table 3.2: Patient Demographics 
 
Analysis of ADRs associated with HAART 
 
On analysis, 117 patients of the cohort experienced at least one ADR in the first year of 
treatment. All observed ADRs occurred within the first 6 months of initiation of HAART with 
the exception of renal ADRs. Renal ADRs were only observed at least 8 months after HAART 
initiation.The overall incidence of ADRs to HAART was found to be 24.95%. Eleven patients 
experienced two ADRs. The majority of ADRs reported were experienced by female patients 
(n=68, 58.1%) as opposed to male patients (n=49, 41.9%).   
 
This study found AZT-based HAART regimens had a higher ADR incidence (n=10, 66.67%), 
compared to TDF-based HAART regimens (n=107, 23.57%). The ADRs were observed with 
the following regimens tenofovir + emtricitabine + efavirenz (88,0% ); tenofovir + lamivudine 
+ efavirenz (3.4%); zidovudine + lamivudine + efavirenz(6.1%) and zidovudine + lamivudine 
+ nevirapine(2.5%). 
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Causality for ADRs observed was classified as “possible”, as per the WHO Causality 
Assessment Tool. ADRs met the following criteria to be classified as “possible”: 
x The event is a specific clinical or laboratory phenomenon linked to HAART. The time 
elapsed between the administration of the drug and the occurrence of the event is 
plausible.  
x The dates of drug administration and date of onset of the event was documented. 
Patients received the anti-retroviral medicines prior to the first mention of the event of 
interest 
x The outcome of withdrawal of the suspected medicine was not known and the medicine 
was not withdrawn 
 
All observed and documented ADRs did not warrant a change in treatment and neither did they 
require an antidote. As a result, they were classified as mild according to the Hartwig Scale. 
 
The ADRs reported with the use of TDF and AZT based HAART regimens were rash  (n=45, 
27%), decreased glomerular filtration rate (n=34, 21%), trouble sleeping (n=39, 21%), severe 
diarrhoea (n=19, 12%), nausea and vomitting (n=18, 11%), decreased heamoglobin or anaemia 
(n=4, 2%), headaches (n=4, 2%), dizziness (n=2, 5.3%).  
 
Factors Influencing ADR occurance  
The ADRs observed were analysed  for factors influencing their incidence. The factors 
analysed were age at initiation of HAART, CD4 count at HAART initiation and adherence. 
viral load  
Proportion of patients with undetectable Viral Load at HAART start (P=.341) and adherence 
(P=.229) were found not to be statistically significantly different  between the patients who 
experienced  ADRs (present) and those who did not (absent). Age at HAART initiation 
(P=.020)  and CD4 count at initiation of HAART (P=0.002) were the only factors found to 
have a statistically significant outcome as patients that experienced ADRs reported a lower 
CD4 count and a lower average age at HAART initiation as presented in Table 3.3. 
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TDF based AZT based 
Total ADR 
Present vs 
ADR 
Absent 
TDF based 
VS AZT 
based 
  
ADR 
Present 
ADR 
Absent p-value 
ADR 
Present 
ADR 
Absent 
p-
value p-value p-value 
Age at 
HAART 
initiation  
35,19 37,22 0,053 31,60 33,00 0,756 0,024 0,060 
CD4 Count at 
HAART 
Initiation  
(Cells/µl) 
338,77 417,08 0,000 277,90 500,80 0,097 0,002 0,001 
Adherence 
94,20% 93,30% 0,176 91,18% 93,55% 0,230 0,229 0,644 
Proportion of 
patients with 
undetectable 
Viral Load at 
HAART start 
69% 59% 0,251 38% 21% 0,091 0,341 0,294 
Number of 
days on 
HAART 
412 415 0,351 400 401 0,966 0,232 0,08 
Creatinine 
Clearance at 
HAART 
Initiation  
(Cells/µl) 86,87 84,18 0,084 
 
Table 3.3: Factors influencing the incidence of ADRs 
 
 
Cost Analysis 
Table 3.4 summarises HAART costs, laboratory costs and total costs obtained on analysis. 
HAART costs within regimens were not significantly different between the patients who 
experienced ADRs compared to the patients who did not (P=.10). On the contrary, laboratory 
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(P=.003) and total direct costs (P<.001) where significantly higher in patients with ADRs for 
both  regimens 
 
 
 TDF based   AZT based   
 
ADR 
Present 
ADR 
Absent p-value 
ADR 
Present 
ADR 
Absent p-value 
Total 
HAART 
Costs R1 733,81 R1 733,13 0,986 R1 312,50 R1 281,00 0,629 
Total 
Laboratory 
Costs R1 687,24 R1 630,76 0,003 R2 227,12 R1 917,29 0,003 
ADR Meds 
Cost R10,01 R0.00 0,001 R26.55 R0.00 0,001 
Total Costs R3 795,79 R3 368,49 0,000 R3 666,17 R3 198,23 0,004 
Table 3.4:Components of charges Analysed 
 
The above ADRs were further grouped according to the body system the drug(s) affected as 
presented in Table 3.5. Analysis of the ADRs was then carried out as per body system. Costs 
attributed to GI related ADRs were highest in comparison with other ADRs for both HAART 
regimens.  
 
Regimen ADRs 
No of 
ADRs  Incidence 
 Total mean 
direct cost  
Mean 
direct cost 
per ADR 
per 
annum 
p-
value 
AZT 
based GI Related 6 40,00%  R      3 637,30  R439,07 0,004 
  CNS Related 1 6,00%  R      3 639,97  R441,74 0,017 
  Dermatologic 4 26,67%  R      3 327,18  R128,95 0,035 
  Haematological 4 26,67%  R      3 458,14  R259,91 0,043 
TDF 
based GI Related 31 6,83%  R      3 458,59  R90,10 0,009 
  CNS Related 40 8,81%  R      3 432,71  R64,22 0,032 
  Dermatologic 43 9,47%  R      3 504,31  R135,82 0,000 
  Renal 34 7,49%  R      3 566,25  R197,76 0,000 
Table 3.5: Incidence and Mean Direct Cost per ADR per annum  
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The study found that ZAR427.30 attributed to ADRs due to TDF-based regimens compared 
to ZAR467.94 attributed to ADRs due to AZT-based regimens per patient during the first 
year of treatment. 
 
Budget Impact Analysis  
A decision tree model was developed to estimate annual cost associated with ADRs at a clinic. 
The incidences rates of ADRs observed in above analysis were utilised as probabilities of 
occurrence of the ADRs as presented in Figure 3.2. Cost per ADR used in the model were 
derived from the retrospective chart review carried out. Conditional probabilities were derived 
from the decision tree analysis.  
 
Fig 3.2: A decision-tree model used in the budget impact analysis 
For AZT-based regimens, the following conditional probabilities were derived; gastro-
intestinal related (p=0,0085), central nervous system-related (p=0,00128), haematological 
(p=0,00576) and dermatologic (p=0,00576). For TDF-based regimen, the following 
conditional probabilities were derived; gastro-intestinal-related (p=0,04797), central nervous 
system related(p=0,06168), dermatologic (p=0,06625), and renal (p=0,05254).This analysis 
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was based on the number of patients initiated on TDF- or AZT-based HAART during the year 
analysed, which is 1221 patients (Fig 1: Sampling Flow Chart). 
 
The model estimated costs attributable to ADRs associated with TDF-based HAART as 
follows; gastro-intestinal related ADRs (ZAR5 277,73), central nervous system related ADRs 
(ZAR4 836,57), dermatologic ADRs (ZAR10 986,64) and renal ADRs (RZA12 687,30). With 
AZT-based HAART, the model estimated costs attributable to ADRs as follows: GI-related 
ADRs (ZAR4 577,05), CNS related ADRs (ZAR690,73), dermatologic ADRs (ZAR907,35) 
and heamatologic ADRs (ZAR1828,85). Fig 3 details the predicted costs per annum of ADRS 
in South African Rands. 
 
Fig 3.3: Predicted Costs of ADRs per Annum 
 
In order to simplify comparison with results of previous studies, final costs were converted to 
US dollars using the rate of US$1 equivalent to ZAR14.3853.28 Estimated total cost of ADRs 
attributed to AZT based HAART is ZAR8003.98 (US$556.40)  and estimated total cost of 
ADRs attributed to TDF based HAART per annum is ZAR33 788.23 (US$2 348.80).  
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Sensitivity Analysis 
Fig 4 presents side-by-side two-way sensitivity analysis of costs attributable to ADRs of TDF-
based and AZT-based HAART. Mean costs attributable to ADRs as well as ADR incidence 
were the variables. Costs attributable to ADRs for TDF-based HAART rose as high as 
ZAR83 948.06 (US$5 835.68) whilst costs attributable to ADRs for AZT-based HAART rose 
as high as ZAR13 150.81(US$914.18). 
 
 
Fig 3.4: Sensitivity Analysis of Costs Attributable to ADRs of Tenofovir Based and Zidovudine 
Based HAART Side by Side 
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Discussion 
The aim of the study was to identify adverse drug reactions attributable to TDF- and AZT-
based fixed-dose combinations of HAART, and subsequently, determine the annual costs 
incurred managing these adverse drug reactions and the budget impact of these costs in an 
outpatient anti-retroviral clinic. Baseline characteristics were not significantly different 
between the cases and controls except for baseline CD4 count and age at HAART initiation. 
This is in line with previous studies that have shown that lower CD4 counts had a propensity 
for increased risk of ADR occurrence.29All ADRs observed were classified as mild in terms of 
severity. This was expected, as moderate and severe ADRs would likely require a change in 
treatment or hospitalisation that would have resulted in exclusion from the analysis.  
The overall incidence of ADRs to HAART was found to be 24.95%. This is comparable, 
though lower, to another study carried out in South Africa that reported an incidence of 37%.30  
The incidence was however notably lower in comparison to other studies which recorded 
incidences as high as 89%.16, 17, 18, 19  The relatively lower incidence could have been due to the 
fact that patients with co-morbidities were excluded in the analysis. It has been previously 
reported that patients with comorbidities are three times more likely to experience an ADR 
than those with no comorbidities.31  
Prior studies on costs attributable to ADRs of HAART are limited, especially in developing 
countries. This study found that per patient costs attributed to ADRs due to TDF-based 
regimens and AZT-based regimens during the first year of treatment where ZAR427.30 
(US$29.70) and ZAR467.94 (US$32.53) respectively. Costs attributable to ADRs observed in 
this study were notably lower than those observed in studies carried out in the USA. 32-34 
Although costs attributable to ADRs of HAART are lower in developing counties, when 
national per capita spending on health is factored as well budget impact, the costs remain 
significant. 
Johnston et al.(2013) reported the costs attributable to ADRs ranging from US$ 3 to US$ 43 
per ADR per month.32 Therefore their per annum figures would be approximately 12 times 
more compared to those observed in our study. Similarly, Simpson et al. (2014) reported mean 
costs associated with managing an AE-associated costs as $608.33 In a study carried out in 
India, Radhakrishnan et al. (2012) reported mean direct cost incurred in treating per ADR in 
hospitalized patients with HAART as ranging from INR 524.4 (US$ 11.4) to INR 17521.4 
 
59 
 
(US$ 380.9).35 This study was carried out in a hospital setting, therefore due to hospitalization, 
the costs attributable to ADRs would be higher than our observed costs. Despite being slightly 
higher than the costs we observed, their costs were also very low compared to those reported 
in studies from developed countries.32-34 
Estimated total cost of ADRs attributed to AZT-based HAART is R8003.98 (US$556.40) and 
estimated total cost of ADRs attributed to TDF-based HAART per annum is R33 788.23 
(US$2348.80). As expected, the estimate is even lower compared to costs observed in studies 
carried out in developed countries. Johnston et al. (2013) found that total healthcare costs 
attributable to ADRs were $13 000 over 12 months.32 When other factors are taken into 
consideration, this value might be an underestimate. Radhakrishnan et al. (2012) found that as 
severity of ADRs increased, costs associated with ADRs also markedly increased. 35 Co-
morbidities and polypharmacy have also been found as a risk factor for increased incidence 
and severity of ADRs to HAART.32 Our study excluded patients with co-morbidities; therefore, 
the value estimated could also be underestimated.  
Conclusion 
Adverse drug reactions impact on adherence to HAART. Prevention and management of ADRs 
and costs thereof are tantamount to the success of HAART. Despite our estimated costs being 
lower that other studies, they can be significant in a resource limited setting. Any funds 
allocated to management of ADRs are funds directly taken away from other healthcare 
functions such as treatment or staffing, in such a setting.  These estimates will allow for cost 
implications of ADRs to TDF and AZT-based HAART to be accounted for in budgets at the 
ARV clinic. 
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CHAPTER 4  
CONCLUSIONS 
 
4.1 Introduction 
This study was carried out to identify adverse drug reactions attributable to tenofovir- and 
zidovudine-based fixed-dose combinations of highly active anti-retroviral therapy and, 
subsequently, to determine the annual costs incurred managing these adverse drug reactions 
and the budget implications of this in an outpatient anti-retroviral clinic. The rationale of this 
study was based on previous research conducted in other countries, which showed significantly 
high costs of managing, and preventing ADRs associated with HAART.1-5 There were no 
studies in South Africa analyzing costs attributable to ADRs. This gap identified led to this 
study being carried out.  
 
4.1.1 Strengths of the study methodology and design  
The study was a retrospective chart analysis; therefore, minimal costs were involved with data 
collection.  
 
4.1.2 Limitations of the study 
• Data was collected from routine medical charts not intended for research purposes and 
therefore prone to reporting bias, which results in underreporting. 
• Severity of ADRs was not reported in the medical charts. The investigator deduced it 
with no second opinion. 
• Indirect cost such as disability, work productivity losses related to absenteeism and other 
financial cost was also associated in the management of HIV/AIDS. These costs however 
were not analysed due to the limited scope of the study. 
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4.2 Conclusions drawn from the study findings 
 
4.2.1 Analysis of ADRs associated with HAART 
Baseline characteristics were not significantly different between the participants with ADRs 
and those without except for baseline CD4 count. This congruent with a previous study which 
have shown that lower CD4 counts had a propensity for increased risk of ADR occurrence.6 
 All ADRs observed were classified as mild in terms of severity. This was expected as moderate 
and severe ADRs would likely require a change in treatment or hospitalisation, which would 
have resulted in exclusion from the analysis. The observed ADRs mostly occurred within the 
first 6 months after treatment initiation except for the renal ADRs, which were mostly noted 
after 6months on treatment.  Studies have shown that most ADRs to HAART occur within the 
first year of treatment.7, 8 
The overall incidence of ADRs to HAART was found to be 24.95%. This is comparable, 
though lower, to another study also carried out in South Africa, which reported an incidence of 
adverse drug reactions (ADRs) to HAART as 37%. 9 The incidence in our study was however 
significantly lower in comparison other studies which recorded incidences as high as 89%.10, 
11, 12, 13 The relatively lower incidence could have been because patients with co-morbidities 
were excluded in analysis. Patients with comorbidities are three times more likely to experience 
an adverse drug reaction than those with no comorbidities.14  
 
4.2.2 Cost Analysis 
Prior studies on costs attributable to ADRs of HAART are limited, especially in developing 
countries. This study found that costs attributed to ADRs due to TDF based regimens and AZT 
based regimens during the first year of treatment were R427.30 (US$29.70) and R467.94 
(US$32.53) respectively. Costs attributable to ADRs observed in this study were significantly 
lower than the costs observed in studies carried out in the USA. 3-5 Although costs attributable 
to ADRs of HAART are lower in developing counties, when national per capita spending on 
health is factored as well budget impact, the costs are significant. 
 Johnston et al. (2013)  reported the costs attributable to ADRs ranging from US$ 3 to US$ 43 
per ADR per month.3 Therefore their per annum figures would be approximately 12 times more 
compared to those observed in our study. Similarly, Simpson et al. (2014) reported mean costs 
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associated with managing an AE-associated costs as $608.4 In a study carried out in India, 
Radhakrishnan et al. (2012) reported mean direct cost incurred in treating per ADR in 
hospitalized patients with HAART as ranging from INR 524.4 (US$ 11.4) to INR 17521.4 
(US$ 380.9). 2 This study was carried out in a hospital setting, therefore due to hospitalization; 
the costs attributable to ADRs would be higher than our observed costs. Despite the costs in 
this study being higher than the costs we observed, their reported costs were also very low 
compared to those reported in studies from developed countries. 3-5  
Severe adverse drug reactions are generally not treated in an outpatient setting as 
hospitalization would be required. Therefore, costs observed in this study do not reflect those 
attributed by more severe reactions associated with HAART such as Stevens–Johnson 
syndrome (SJS), renal failure or bone demineralization observed in other studies. Severity of 
ADRs has a directly proportionate impact on healthcare costs, i.e. severe ADRs are associated 
with higher costs compared to moderate as well as mild ADRs.2-15  
 
4.2.3 Budget Impact Analysis 
Estimated total cost of ADRs attributed to AZT based HAART is R8003.98 (US$556.40) and 
estimated total cost of ADRs attributed to TDF based HAART per annum is R33 788, 23 
(US$2348.80). Although modest, these figures influence the ARV clinic s pharmaceutical 
budget.  
When other factors are taken into consideration, this value might be an underestimate. 
Radhakrishnan et al. (2012) found that as severity of ADRs increased, costs associated with 
ADRs also markedly increased.2 Our study, excluded patients with co-morbidities therefore the 
value estimated could also be underestimated as it has been reported that co-morbidities and 
polypharmacy are risk factors for increased ADR incidence rates.14 Sensitivity analysis carried 
out reveals that increasing incidence of ADRs markedly increased the estimate costs 
attributable to ADRs.  
 
4.3 Significance of the study 
 Adverse drug reactions influence adherence to HAART. Prevention and management of ADRs 
and costs thereof are tantamount to the success of HAART. Analysis of the costs of HAART 
would be insufficient if the costs of adverse drug reactions associated with them are not 
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factored as well.16 This scenario advocates for more knowledge of the cost implications of 
ADRs to HAART. Studies on the costs attributable to ADRs and the budget impact of these 
costs are limited especially in South Africa.  
One of the results of the NDoH ARV rollout programmes is that an unprecedented number of 
patients are initiated on HAART. The consideration of the health care costs of ADRs is 
paramount in understanding the total impact on the costs of managing HIV. This study 
contributes to the knowledge of the economic burden of ADRs to HAART. 
 
4.4 Recommendations 
Research on the cost of ADRs relies on good pharmacovigilance systems as well as record 
keeping systems. South African pharmacovigilance systems are currently being improved or 
initiated in many government institutions. As these systems improve, it is of great importance 
to look into larger research studies, which utilise economic modelling systems to ascertain the 
cost of HAART ADRs. 
 
Despite our estimated costs being lower than those of other studies, they are significant in a 
resource-limited setting. In a resource-limited setting, any funds allocated to management of 
ADRs are funds directly taken away from other functions such as additional patients on 
HAART or additional staff members.  These estimates will allow for cost implications of ADRs 
to TDF and AZT-based HAART to be accounted for in budgets at the ARV clinic. More CHCs 
will have to be surveyed to enable proper and more diverse recommendations on the costs 
attributable to HAART 
 
4.5 Chapter summary 
This final chapter highlighted the conclusions drawn from the findings of the study, described 
the significance, strengths and limitations of the study, as well as provided recommendations 
for pharmacoeconomic analysis of adverse drug reactions of HAART. 
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